Evidence supporting the use of: Cannabidiol
For the health condition: Anxiety Disorders

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Cannabidiol (CBD) has garnered significant interest as a potential treatment for anxiety disorders. Several preclinical studies using animal models have suggested that CBD exerts anxiolytic (anxiety-reducing) effects, possibly by interacting with serotonin (5-HT1A) receptors and modulating the endocannabinoid system. In humans, a handful of small randomized controlled trials (RCTs) and experimental studies have provided preliminary evidence supporting CBD’s anxiolytic properties. For example, a 2011 study published in Neuropsychopharmacology found that acute administration of CBD (600 mg) reduced anxiety in subjects with social anxiety disorder during a simulated public speaking test. Additional small trials and case series have reported improvements in anxiety symptoms among patients with generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder (PTSD).

However, the overall quality of evidence is limited by small sample sizes, short durations, heterogeneity of dosing, and lack of standardization in CBD preparations. Systematic reviews and meta-analyses (such as Blessing et al., 2015, and Skelley et al., 2020) conclude that while early findings are promising, robust clinical trials are needed to confirm efficacy, determine optimal dosing, and assess long-term safety. Currently, CBD is not an FDA-approved treatment for anxiety disorders. In summary, there is emerging but not definitive scientific evidence supporting the use of cannabidiol for anxiety disorders.

More about Cannabidiol
More about Anxiety Disorders

Products containing Cannabidiol

We currently have no products on Vitabase that contain this ingredient.